🔍

LUPIN - Lupin

📊 NSE: LUPIN 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:20

📢 Recent Corporate Announcements

Lupin's Ankleshwar Facility Receives US FDA Form-483 with 2 Observations

🔵 WATCH ⭐ 7/10

REGULATORY 📅 07 Mar 2026, 05:55 PM

The U.S. FDA concluded a six-day inspection at Lupin's manufacturing facility in Ankleshwar, India, on March 07, 2026. The inspection resulted in the issuance of a Form-483 with two observations regarding manufacturing practices. Lupin has stated it will address these observations and respond to the regulator within the stipulated timeframe to ensure CGMP compliance. While the number of observations is low, the impact depends on their technical severity and the company's ability to remediate them quickly.

U.S. FDA inspection conducted at the Ankleshwar facility from March 02 to March 07, 2026.
The inspection concluded with the issuance of a Form-483 containing 2 observations.
Lupin is required to respond to the U.S. FDA within the stipulated timeframe to address findings.
Company maintains commitment to CGMP standards across all manufacturing facilities.

💡 Investors should monitor for the final classification of the inspection (VAI or OAI) as significant observations could lead to regulatory escalations. The low number of observations is generally manageable, but the specific nature of the findings will determine the long-term impact on US exports.

Lupin Announces Conclusion of GST Inspection with No Immediate Financial Impact

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 02 Mar 2026, 08:58 PM

Lupin Limited has reported the conclusion of inspection and search proceedings by the Maharashtra GST Department at its registered office on March 02, 2026. The search, which commenced on February 25, 2026, ended at 08:15 p.m. without any official communication regarding adverse findings. The company has stated that all requested information was provided and there is currently no impact on its financial statements. While the immediate search is over, investors should remain aware that tax authorities may still issue formal assessments later.

GST Department, Maharashtra concluded search proceedings on March 02, 2026, at 08:15 p.m.
The inspection followed an initial intimation of proceedings dated February 25, 2026.
No official communication regarding adverse findings has been issued by the GST Department.
Lupin confirms there is currently no impact on the financials of the company.
All necessary documents and information were provided to authorities during the process.

💡 Investors should view this as a routine regulatory closure with no immediate financial threat. Monitor future disclosures for any potential tax demand notices that could arise from the final assessment of this search.

Lupin Delays Acquisition of VISUfarma B.V. to April 2026

🟡 NEUTRAL ⭐ 7/10

M&A 📅 27 Feb 2026, 04:51 PM

Lupin Limited has announced a timeline extension for the acquisition of VISUfarma B.V. by its subsidiary, Nanomi B.V. The transaction, which involves acquiring 100% of the share capital, was previously expected to conclude by February 28, 2026. The company now anticipates completion in April 2026, pending the satisfaction of specific closing conditions. This acquisition is a strategic move to strengthen Lupin's presence in the European pharmaceutical market.

Acquisition of 100% share capital of Netherlands-based VISUfarma B.V. by Lupin's subsidiary Nanomi B.V.
Completion timeline extended from February 28, 2026, to April 2026.
Delay is attributed to the ongoing fulfillment of specific closing conditions.
Follows previous regulatory updates provided on September 29, 2025, and December 30, 2025.

💡 Investors should view this as a minor procedural delay rather than a deal cancellation. Monitor for the final completion announcement in April 2026 to assess the impact on Lupin's international revenue growth.

Lupin Receives US FDA EIR with Satisfactory VAI Status for Goa Facility

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 27 Feb 2026, 01:00 PM

Lupin Limited has successfully received the Establishment Inspection Report (EIR) from the US FDA for its Goa manufacturing facility. The report follows an 11-day inspection conducted from November 10 to November 21, 2025. The facility has been assigned a Voluntary Action Indicated (VAI) classification, which is considered a satisfactory regulatory outcome. This clearance is crucial for Lupin as it ensures the continued supply and potential for new product approvals from this key export site to the US market.

Received US FDA EIR for the Goa facility with a satisfactory VAI classification.
The inspection was conducted over an 11-day period from November 10 to November 21, 2025.
VAI status indicates that the facility meets regulatory standards despite minor observations.
This clearance supports Lupin's global supply chain and US market growth strategy.

💡 This is a positive development that removes a significant regulatory overhang for the Goa plant. Investors should monitor for potential new product approvals from this site that may have been pending the inspection outcome.

Lupin CEO Vinita Gupta Named to 2026 CNBC Changemakers List for U.S. Market Impact

🟢 POSITIVE ⭐ 3/10

OTHER 📅 26 Feb 2026, 08:42 PM

Lupin CEO Vinita Gupta has been recognized on the 2026 CNBC Changemakers list for her leadership in expanding affordable medicine in the U.S. Under her tenure, Lupin has become the 3rd largest generic medicine supplier in the U.S. and the 7th largest pharmaceutical company globally by volume. The recognition highlights Lupin's strategic milestones, including the late 2025 FDA approval of its first biosimilar, Pegfilgrastim. The company is also advancing its U.S. presence with a new state-of-the-art inhalation facility in Florida.

CEO Vinita Gupta recognized on the 2026 CNBC Changemakers List for transforming business and medicine accessibility.
Lupin ranks as the 3rd largest generic supplier in the U.S. and 7th largest pharmaceutical company globally by volume.
Achieved pivotal FDA approval for its first biosimilar, Pegfilgrastim, in late 2025.
Expanding U.S. manufacturing with a new inhalation facility in Coral Springs, Florida, for products like Albuterol.
Global infrastructure includes 15 manufacturing sites, 7 research centers, and a workforce of over 24,000 professionals.

💡 This recognition underscores the strength of Lupin's leadership and its successful penetration into the complex U.S. generics and biosimilars market. Investors should view this as a positive brand-building event that validates the company's long-term growth strategy in high-value respiratory and biosimilar segments.

Lupin Ranks #1 Globally in Pharma with 91/100 Score in S&P ESG Assessment 2025

🟢 POSITIVE ⭐ 6/10

OTHER 📅 26 Feb 2026, 07:56 PM

Lupin has achieved the top global rank in the pharmaceutical sector in the 2025 S&P Global Corporate Sustainability Assessment (CSA) with a score of 91 out of 100. This score places Lupin in the top 1% of over 9,200 companies evaluated across 59 industries worldwide. Additionally, the company has been recognized as the leader across all sectors in India, surpassing both domestic and international peers. This marks Lupin's third consecutive year of inclusion in the S&P Sustainability Yearbook, reflecting strong governance and environmental stewardship.

Achieved a score of 91 out of 100 in the S&P Global Corporate Sustainability Assessment (CSA)
Ranked No. 1 globally in the pharmaceutical industry and No. 1 across all sectors in India
Placed within the top 1% of more than 9,200 companies assessed globally
Included in the Sustainability Yearbook 2026 for the third consecutive year
One of only 848 companies to earn Yearbook inclusion out of 9,200+ assessed

💡 This recognition enhances Lupin's appeal to institutional and ESG-focused investors, potentially leading to increased capital inflows. Investors should consider this a positive indicator of the company's long-term operational resilience and governance standards.

Lupin Ranks #1 Globally in Pharma with 91/100 S&P ESG Score

🟢 POSITIVE ⭐ 6/10

OTHER 📅 26 Feb 2026, 04:34 PM

Lupin Limited has achieved the top global rank in the pharmaceutical sector in the S&P Global Corporate Sustainability Assessment 2025. The company secured a score of 91 out of 100, placing it in the top 1% of companies worldwide. Notably, Lupin also ranked as the leader across all sectors in India, surpassing both domestic and international peers. This marks the third consecutive year Lupin has been included in the S&P Sustainability Yearbook, which features only 848 companies out of over 9,200 assessed.

Achieved a score of 91/100 in the S&P Global Corporate Sustainability Assessment 2025.
Ranked #1 globally in the pharmaceutical industry and #1 across all sectors in India.
Placed within the top 1% of companies worldwide for sustainability performance.
Included in the S&P Sustainability Yearbook 2026 for the third consecutive year.
Outperformed over 9,200 companies assessed across 59 different industries globally.

💡 Investors should view this as a positive indicator of Lupin's strong governance and risk management, which often attracts long-term institutional capital. It reinforces the company's premium positioning in the ESG-conscious investment landscape.

Lupin Faces GST Inspection and Search at Registered Office in Mumbai

🔵 WATCH ⭐ 6/10

REGULATORY 📅 25 Feb 2026, 04:45 PM

Lupin Limited has reported that the Maharashtra Goods & Service Tax Department initiated an inspection and search at its registered office on February 25, 2026. The search, conducted under Section 67 of the MGST Act, 2017, pertains to the verification of GST payments and Input Tax Credit (ITC) claims. The company is currently cooperating with officials and has stated that there is no immediate impact on its financial or operational activities. Investors should note that such inspections are procedural but can lead to future tax demands if discrepancies are found.

GST Department initiated search proceedings at Lupin's Mumbai office on February 25, 2026, at 11:50 AM.
The inspection is being conducted under Section 67 of the Maharashtra GST Act, 2017.
Authorities are seeking documents specifically related to GST payments and Input Tax Credit (ITC) claims.
Lupin reports no current quantifiable impact on its financial or operational performance.
The company is extending full cooperation and providing all necessary documentation to the tax officials.

💡 Investors should monitor for subsequent updates regarding any potential tax demands or litigation resulting from this search. No immediate action is required as operations remain unaffected, but tax-related developments can impact future cash flows.

Lupin Launches Brivaracetam Oral Solution in US Targeting $135 Million Market

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Feb 2026, 07:13 PM

Lupin Limited has received US FDA approval and commenced the launch of Brivaracetam Oral Solution (10 mg/mL) in the United States. The product is a generic equivalent of UCB's Briviact, used for treating partial-onset seizures in patients aged 1 month and older. According to IQVIA data, the annual sales for this product in the US were approximately USD 135 million as of December 2025. This launch further strengthens Lupin's presence in the US Central Nervous System (CNS) therapeutic segment.

Received US FDA approval for Brivaracetam Oral Solution 10 mg/mL ANDA
Product is the bioequivalent to Briviact Oral Solution by UCB, Inc.
Targets a US market size estimated at USD 135 million per IQVIA MAT Dec 2025 data
Indicated for partial-onset seizures in patients 1 month of age and older
Immediate launch initiated in the United States market following approval

💡 Investors should monitor the ramp-up of this product as it contributes to Lupin's high-margin US generic portfolio. The launch is a positive development for the company's CNS segment and overall US revenue growth.

Lupin Receives European Commission Approval for Biosimilar Ranibizumab (Ranluspec™)

🟢 POSITIVE ⭐ 8/10

REGULATORY 📅 23 Feb 2026, 03:27 PM

Lupin has received marketing authorization from the European Commission for its biosimilar Ranibizumab, branded as Ranluspec™, available in vials and pre-filled syringes. The approval covers critical ophthalmic indications including wet age-related macular degeneration and diabetic macular edema. Lupin has partnered with Sandoz for commercialization across the European Union (excluding Germany) and with both Sandoz and Biogaran in France. This milestone validates Lupin's biotechnology capabilities and strengthens its portfolio in the high-growth biosimilars market.

European Commission approval granted for Ranluspec™ (biosimilar Ranibizumab) for multiple ophthalmic indications.
Approval includes both vial and pre-filled syringe formats, enhancing delivery options for healthcare providers.
Strategic commercialization partnership formed with Sandoz for the EU market, excluding Germany.
Specific dual-partner commercialization strategy implemented for the French market with Sandoz and Biogaran.
The product targets high-value therapeutic areas such as neovascular (wet) age-related macular degeneration and diabetic macular edema.

💡 Investors should view this as a significant positive development that expands Lupin's high-margin biologics portfolio in regulated markets. Monitor the commercial rollout and subsequent market share gains in Europe to assess long-term revenue impact.

Lupin to Participate in Kotak and IIFL Investor Conferences in February 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 19 Feb 2026, 05:50 PM

Lupin Limited has announced its participation in two upcoming institutional investor conferences scheduled for late February 2026. The company will attend the Kotak Chasing Growth 2026 Conference on February 24 and the IIFL 17th Enterprising India Global Investors Conference on February 26. Both events will consist of in-person group meetings with analysts and institutional investors. The company has clarified that no new material information will be shared, and presentations will align with existing public disclosures.

Scheduled participation in the Kotak Chasing Growth 2026 Conference on February 24, 2026.
Attendance at the IIFL 17th Enterprising India Global Investors Conference on February 26, 2026.
Both events are designated as in-person group meetings for institutional investors.
Presentations will be based on information already available on the Company and Stock Exchange websites.
Disclosure made pursuant to Regulation 30 of SEBI Listing Regulations.

💡 Investors should monitor for any post-conference analyst notes or management commentary that may provide insights into the company's growth outlook. No immediate portfolio action is required based on this routine scheduling update.

Lupin Partners with Spektus to Launch Novel Antidepressant DeslaFlex in Canada

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 16 Feb 2026, 04:00 PM

Lupin Limited has signed a strategic license and supply agreement with Spektus Pharma to commercialize DeslaFlex™, a novel antidepressant, in the Canadian market. DeslaFlex™ utilizes the proprietary Flexitab™ oral drug-delivery platform to treat Major Depressive Disorder with enhanced dosing flexibility. This partnership leverages Lupin's established commercial infrastructure in Canada to expand its Central Nervous System (CNS) portfolio. The collaboration is part of Lupin's broader strategy to introduce value-added, physician-endorsed specialty therapies in developed markets.

Exclusive license and supply agreement for the commercialization of DeslaFlex™ in Canada.
Targeted at Major Depressive Disorder using the proprietary Flexitab™ drug-delivery platform.
Strengthens Lupin's CNS portfolio and global specialty business footprint.
Lupin maintains a global presence with 15 manufacturing sites and 7 research centers.
The agreement marks Spektus Pharma's transition from development to commercial execution.

💡 Investors should monitor the commercial rollout and market share gains of DeslaFlex™ in Canada as it represents a high-margin specialty product addition. This move reinforces Lupin's growth potential in the CNS segment within developed markets.

Lupin Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 13 Feb 2026, 11:33 PM

Lupin Limited has officially released the audio recording link for its Q3 FY26 earnings conference call held on February 13, 2026. The call discussed the company's unaudited financial results for the quarter and nine-month period ended December 31, 2025. This disclosure is a routine regulatory requirement following the announcement of quarterly financial performance. Investors can access the recording on the company's website to hear management's detailed commentary on operational performance and future outlook.

Audio recording of the Q3 FY26 earnings call is now available via the company's website.
The call covered financial performance for the quarter and nine months ended December 31, 2025.
The session was conducted digitally on February 13, 2026, at 16:00 hrs IST.
Compliance filing made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

💡 Investors should listen to the recording to understand management's guidance on the US product pipeline and domestic market growth. No immediate action is required as this is a routine administrative filing.

Anand Kripalu Joins Lupin Board as Independent Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 13 Feb 2026, 07:50 PM

Lupin Limited has appointed Anand Kripalu as an Independent Director to its Board, effective February 13, 2026. Kripalu brings over 30 years of leadership experience from the FMCG sector, having served as MD and Global CEO of EPL Limited and CEO of Diageo India. His extensive background includes 20 years at Unilever and leadership roles at Mondelez International. This appointment is expected to strengthen Lupin's strategic oversight and global market positioning.

Anand Kripalu appointed as Independent Director with over 30 years of FMCG leadership experience.
Previously served as Managing Director and Global CEO of EPL Limited until December 31, 2025.
Held senior leadership roles at Diageo India (MD & CEO) and Mondelez International (President - India & SE Asia).
Currently serves on the boards of Swiggy Limited and United Breweries Limited.
Educational background includes degrees from IIT Madras and IIM Calcutta, plus an AMP from Wharton.

💡 Investors should view this as a positive corporate governance move that adds significant consumer-market expertise to the board. No immediate action is required, but the appointment may help refine Lupin's domestic and global branding strategies.

Lupin Shareholders Approve Appointment of Anand Kripalu as Independent Director

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 13 Feb 2026, 07:34 PM

Lupin Limited has announced that its shareholders have approved the appointment of Mr. Anand Kripalu as an Independent Director through a special resolution. The voting, conducted via postal ballot, saw a high participation rate with 90.17% of total shares represented. The resolution passed with a significant majority, as 96.54% of the total votes cast were in favor of the appointment. This move strengthens the company's board governance with the addition of an experienced professional.

Special resolution for the appointment of Anand Kripalu passed with 96.54% votes in favor.
Total voter turnout was robust at 90.17%, representing 411,905,910 shares.
Promoter and Promoter Group voted 100% in favor of the resolution with 214.2 million votes.
Public Institutional shareholders supported the move with 92.76% of their votes cast in favor.
The appointment was finalized on February 13, 2026, following the conclusion of the remote e-voting period.

💡 Investors should view this as a positive step in strengthening corporate governance. No immediate portfolio action is required, but the addition of experienced independent directors is generally favorable for long-term oversight.

View All LUPIN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Formulations segment accounted for 92.6% of consolidated revenues in 9M FY2024, while the API segment contributed 6.0%. The API business grew 3% YoY to INR 1,177.2 Cr in FY2025. Consolidated revenue grew 13.5% YoY in FY2025 to INR 22,707.9 Cr and 24% YoY in Q2 FY2026 to INR 7,048 Cr.

Geographic Revenue Split

In FY2025, North America contributed 38% (up 16% YoY), India 34% (INR 7,577.3 Cr, up 14% YoY), EMEA 11% (up 22% YoY), Growth Markets 9% (up 7% YoY), and API business 5%.

Profitability Margins

Operating profit margin (OPM) improved to 18.6% in 9M FY2024 from 10.8% in FY2023. Profit Before Tax (PBT) increased by 65.8% in FY2025. Return on Capital Employed (ROCE) reached 25% by the end of Q2 FY2026, up from 21.6% in FY2025.

EBITDA Margin

EBITDA margin for Q2 FY2026 was approximately 24-25%. Consolidated EBITDA rose 39.4% YoY in FY2025, driven by operating leverage and improved product mix.

Capital Expenditure

Regular capital expenditure is estimated at INR 700-800 Cr per annum, primarily funded through internal accruals.

Credit Rating & Borrowing

Short-term rating reaffirmed at [ICRA]A1+ for INR 3,000 Cr facilities. The company maintains a strong liquidity position with cash and bank balances of INR 5,397.8 Cr as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

Key raw materials include anti-TB APIs and high-potency APIs. Captive API consumption accounts for 75-80% of total requirements, reducing external dependency.

Key Suppliers

Not disclosed in available documents; however, the company is actively working on alternate vendor development to manage gross margins.

Capacity Expansion

Capex of INR 700-800 Cr per annum is planned for maintenance and incremental expansion. Higher capacity utilization at key manufacturing sites has improved operating leverage.

Raw Material Costs

Raw material costs are managed through high captive integration (75-80%). Gross margins improved in FY2025 due to a shift toward complex generics and respiratory products.

Manufacturing Efficiency

Operating leverage improved due to higher capacity utilization and digitization of commercial operations, contributing to a 25% ROCE in Q2 FY2026.

Logistics & Distribution

Distribution costs are optimized through supply chain agility and digitization, though specific INR values were not disclosed.

📈 Strategic Growth

Expected Growth Rate

24%

Growth Strategy

Growth will be driven by a differentiated pipeline in complex generics (inhalations and injectables), biosimilars (Ranibizumab, Pegfilgrastim), and expansion into underpenetrated European markets like Italy and Spain through a EUR 190 million acquisition. India growth is focused on chronic therapies and new verticals like diagnostics.

Products & Services

Anti-TB medicines, anti-diabetes formulations, respiratory inhalers, complex injectables, biosimilars, and diagnostic services.

Brand Portfolio

Lupin, Lupin Manufacturing Solutions (LMS), Enzene (Biosimilars).

New Products/Services

New product launches in the US and India, including biosimilars like Ranibizumab and Pegfilgrastim, are expected to drive significant margin expansion.

Market Expansion

Expansion into Italy and Spain via the acquisition of Nanomi B.V. for EUR 190 million, expected to be completed by December 2025.

Market Share & Ranking

8th largest company in the Indian Pharmaceutical Market (3.4% share) and 3rd largest pharmaceutical player in the US by prescriptions.

Strategic Alliances

Lupin Manufacturing Solutions (LMS) is positioned as a differentiated CDMO partner for global pharma innovators.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and CDMO outsourcing due to 10-15% annual price erosion in commoditized generics. Lupin is positioning itself through high-barrier respiratory products and biosimilars.

Competitive Landscape

Intense competition in US generics and biosimilars, with some players exiting due to pricing pressures, allowing Lupin to gain market share in niche segments.

Competitive Moat

Lupin holds a durable moat as the only WHO pre-qualified company globally for both anti-TB APIs and formulations, alongside a dominant 42% US revenue share from complex inhalations.

Macro Economic Sensitivity

Vulnerable to US healthcare reforms, changes in the US tariff regime, and domestic pricing controls under the National List of Essential Medicines (NLEM).

Consumer Behavior

Increased demand for chronic therapies and diagnostic services in India is driving a 14% growth in the domestic formulation business.

Geopolitical Risks

Trade barriers and regulatory shifts in the US and EU could impact the 49% of revenue derived from these regulated markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA manufacturing standards (warning letters pending for Tarapur and Mandideep) and NLEM pricing controls in India.

Environmental Compliance

The company received an ESG rating from NSE Sustainability Ratings & Analytics Limited in December 2025.

Taxation Policy Impact

Financial statements are prepared in accordance with Indian Accounting Standards (Ind AS).

Legal Contingencies

Ongoing investigation by the US DoJ anti-trust division regarding price fixing and collusion allegations; impact remains an event risk.

⚠️ Risk Analysis

Key Uncertainties

Adverse outcomes from US DoJ investigations or failure to resolve USFDA warning letters could impact revenue by restricting market access or incurring heavy fines.